Navigation Links
Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine

Antigenics Pharmaceuticals is to start its Phase III cancer vaccine trial against Melanoma which is a type of skin cancer. Oncophage is the new skin cancer vaccine developed by Antigenics.// The vaccine trial of Oncophage which was conducted in 322 patients failed to meet the required statistically significance results compared to prolongation in survival and the vaccine was not shown to have any better results compared to other cancer treatments.

But, earlier studies with Oncophage showed a group of patients with the least-advanced severity of melanoma in the trial lived 20.9 months on Oncophage compared to 12.8 months for those patients taking standard drugs, the company said. The difference had not yet reached statistical significance and the trial is continuing.

Antigenics is to start a Phase III study next year to test its vaccine on a more responsive group, patients with Stage IV M1a patients. Though, the trial is to cost the company more than $12 million the scientists of the company are confident over the results.

Needham & Co. analyst Mark Monane in a research note called the data "encouraging" but only "hypothesis-generating rather than hypothesis-confirming, that we believe that any intensive reading into the data at this stage may be premature."
'"/>




Page: 1

Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
3. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
4. Top Pharmaceuticals Influence Doctors Prescriptions
5. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
6. Personalized Medicine and Innovative Pharmaceuticals
7. Pravastatin Launched by Watson Pharmaceuticals
8. Tata Industries picks up stake in Indigene Pharmaceuticals
9. Pharmaceuticals May not Pose Major Aquatic Environmental Risks
10. OPPI Opposes Draft National Pharmaceuticals Policy
11. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... , ... International Dark-Sky Association (IDA) recently bestowed the prestigious ... advanced LED wireless dimming controller, along with the previously IDA approved Dimulator, are ... light pollution. Leo Smith, the Northeast Regional Director for IDA says “We are ...
(Date:9/1/2020)... Calif. (PRWEB) , ... September 01, 2020 , ... As ... “safe side”, the Cohn Health Institute has taken this time to expand ... celebration of its 30th Anniversary, the Cohn Health Institute will be relaunching its brand ...
(Date:8/31/2020)... ... 31, 2020 , ... Ocean Springs, Mississippi-based pharmaceutical distributor Gulf ... responders across the United States. Since the start of the global COVID-19 pandemic, ... medical centers , hospitals , firefighters , and public schools ...
(Date:8/31/2020)... ... 31, 2020 , ... The pandemic and topsy-turvy economic outlook continues to put financial strain on ... ways to trim the fat from our monthly expenses and put more into savings, if ... that you have a financial safety net in place in case something were to happen ...
(Date:8/29/2020)... (PRWEB) , ... August 29, 2020 , ... When professor ... perhaps with greater ease than most people would. Rather than become melancholic, however, he ... deep advice on achieving one’s dreams. Randy Pausch took a negative situation and turned ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Agilent, a global leader ... Science and Technology Virtual Symposium 2020 (ASTVS 2020) on September 10-11, opening ... of Live webinars and Networking sessions, with a vast array of on-demand presentations ...
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... ... has been appointed to serve as Secretary to the Board of Trustees and ... , Mile High United Way is a Denver-based nonprofit organization that fights for ...
(Date:9/1/2020)... ... September 01, 2020 , ... Breast and ovarian cancers are common ... About 3% of breast cancers (about 7,500 women per year) and 10% of ovarian ... BRCA2 genes. Both genes are detectable in the Women’s Excellence Genetic Testing Program. ...
Breaking Medicine Technology: